Physician profile
Komal Patel
NPI 1306417308
$1,089.54
in general payments reported to CMS, 2019-2025
13 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $208 · 2022: $67.05 · 2023: $217 · 2024: $150 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $615 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $614.63 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $328.15 | 2023-2025 | Kxl System (Not Refurbished), Istent Infinite, Idosetr |
| Tarsus Pharmaceuticals, INC. | $194.32 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $169.69 | 2021-2025 | |
| Harrow Eye, LLC | $115.02 | 2025 | Vevye |
| Bausch & Lomb Americas INC. | $72.55 | 2022-2024 | Infuse, Multi-Focal |
| Abbvie INC. | $43.50 | 2024 | |
| Spark Therapeutics, INC. | $36.50 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $31.59 | 2022 | |
| Astellas Pharma US INC | $26.78 | 2024 | Izervay |
| Coopervision INC. | $20.44 | 2024 | Misight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $19.27 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.99 | 2022 | |
| Alcon Vision LLC | $15.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Komal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.